Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

The Phase III, open-label extension study suggests EPX-100 has a “positive” risk/benefit profile for the treatment of Dravet ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ...

The MarketWatch News Department was not involved in the creation of this content.-- Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including ...

Discover Stoke Therapeutics' promising RNA therapies and market outlook. Learn the risks and commercial potential before investing in STOK shares.

It's the fifth year in a row that the property in Beechgrove Place in Perth will be lit up in stunning fashion for two ...

Staff at Tiddlers Nursery in Coventry have been praised for the care and support they have provided to a two-year-old boy ...

Tiddlers Nursery has been crowned Educational Professional of the Year after it went above and beyond for a two-year-old with ...